STEMLINE THERAPEUTICS INC
已退市CIK 1264587fmd_0SCHMX2M6X307PMM19H037R1QD制造业 · 医药制剂模板: 标准
覆盖范围: 2004年1月01日 至 2020年3月31日，共 41 个期间
| 项目 | FY2010 | FY2011 | FY2012 | FY2013 | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 |
|---|---|---|---|---|---|---|---|---|---|---|
| 营业总收入 | – | – | – | – | – | – | 1 | 1 | 1 | – |
| 营业成本 | – | – | – | – | – | – | – | – | – | 5 |
| 研发费用 | – | 2 | 3 | 16 | 21 | 29 | 28 | 50 | 48 | 51 |
| 销售、一般及管理费用 | – | – | – | – | – | – | – | 19 | 39 | 67 |
| 营业费用合计 | – | 3 | 6 | 24 | 29 | 38 | 40 | 69 | 87 | – |
| 营业利润 | – | (3) | (6) | (24) | (29) | (38) | (39) | (69) | (86) | (79) |
| 利息费用 | – | 0 | 0 | 1 | – | – | – | – | 0 | 0 |
| 利息及投资收益 | – | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 3 |
| 其他营业外收入（支出） | – | – | – | – | – | 0 | 0 | (0) | (0) | (0) |
| 税前利润 | – | – | – | – | (29) | (37) | (38) | (68) | (85) | (77) |
| 所得税费用 | – | – | – | – | – | 0 | (0) | 0 | 0 | (0) |
| 持续经营净利润 | (2) | (3) | (6) | (24) | (29) | (37) | (38) | (68) | (85) | (77) |
| 净利润 | – | – | – | – | – | (37) | (38) | (68) | (85) | (77) |
| 归属于普通股股东的净利润 | – | (3) | (6) | (24) | (29) | (37) | (38) | – | – | – |